Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CT-P59 in Healthy Subjects
NCT04525079Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regdanvimab in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Celltrion. Primary endpoint: Preliminary Safety and Tolerability of CT-P59 at Day 14. Started Jul 2020; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04525079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525079.